Company / Gross Profit
Charles River Laboratories Gross Profit History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$211.8M
FY2019
5-year range
-
FY2016-FY2019
Trend
+16.7%
vs FY2018
Sector context
#77 of 100
Health Care
What the data says
Charles River Laboratories's gross profit of $212M is lower than 77% of companies in the Health Care sector (FY2019). Gross Profit has increased for 3 consecutive years, from $141M in FY2016 to $212M in FY2019.
Based on SEC 10-K filings.
$212M in FY2019 with a 3-year CAGR of +14.6%.
Improved from $172M to $212M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +14.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 100This company $211.8M Sector average $1.8B
▼
-88.3% below sector average
Key checks
Key Insights
- Charles River Laboratories's gross profit has grown for 3 consecutive years.
- 3-year CAGR of +14.6%, indicating consistent growth.
- In FY2019, gross profit increased 16.7% year-over-year.
- Ranks #77 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $211.8M | +16.7% |
| FY2018 | $181.5M | +5.7% |
| FY2017 | $171.7M | +22.0% |
| FY2016 | $140.8M | +17.6% |
As of FY2019 · SEC 10-K · Updated Jul 4, 2026